Document is current

Any future updates will be listed below

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

Crossref DOI link: https://doi.org/10.1186/s12876-017-0654-1

Published Online: 2017-08-08

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark